

**Disclosures under Regulation 29(1)/29(2) of SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011**

Part A:

General Details

1	Target Company (TC)	Piramal Pharma Limited		
2	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Deutsche Bank AG, Singapore Branch, DBX Advisors LLC		
3	Stock exchange(s) where the Target company is listed	NSE	BSE	MSEI
		Yes	Yes	NA
4	Nature of Transaction	Acquisition		
5	Mode of Acquisition and/or Disposal	Others	Unlisted shares of the TC were already encumbered by way of security created over the shares of its holding company in favour of Deutsche Bank AG, Singapore Branch (see Notes 1 and 2). The TC was subsequently listed on the stock exchanges on 19 October 2022.	
6	Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc. <i>(Please fill NA, if not relevant)</i>	NA		
7	Date of Acquisition/Disposal <i>(In case shares or voting rights are bought over a period of time, enter "From" and "To" date in DD- MMM-YYYY format)</i>	Single Date	19-Oct-2022	
		Period	From	To
8	Equity share capital / total voting capital of the TC before the said acquisition/disposal	₹11,933,185,000		
9	Equity share capital/ total voting capital of the TC after the said acquisition/Disposal	₹11,933,185,000		

10	Total diluted share/voting capital of the TC after the said acquisition/Disposal	₹11,933,185,000
----	--	-----------------

Remarks (Optional)

11	<p>Additional Information <i>(For Public dissemination)</i></p>	<p>1. Pursuant to the terms and conditions set out in (A) the facility agreement dated 10 May 2021 between, inter alia, CA Alchemy Investments as the borrower (the "Borrower"), Barclays Bank PLC, Barclays Merchant Bank (Singapore) Limited, Deutsche Bank AG, Singapore Branch and Nomura International (Hong Kong) Limited as arrangers, Deutsche Bank AG Singapore Branch as agent, calculation agent and security agent (the "Security Agent") and the lenders named therein (the "Facility Agreement"), and (B) a fixed and floating charge agreement dated 11 May 2021 between inter alia the Borrower, the shareholders of the Borrower (the "Shareholders") and the Security Agent</p> <p>2. As on date, the Borrower holds 20% of the issued and paid up share capital of the Piramal Pharma Limited (on a fully diluted basis).</p> <p>3. As on 8 November 2022, Nomura Singapore Limited and/or Nomura Special Investments Singapore Pte. Limited (being one of the lenders) independently holds 3,878,964 equity shares.</p>	
----	--	---	--

Disclosures under Regulation 29(1)/29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Details of Acquisition/Disposal

Sr. No.	Name(s) of entity/person	Entity/Person		PAN	Nature Of Security	Opening			Acquisiton			Disposal			Closing		
		Promoter/ Promoter Group	PAC			No. of shares	% total	% diluted	No. of shares	% total	% diluted	No. of shares	% total	% diluted	No. of shares	% total	% diluted
1	Deutsche Bank AG, Singapore Branch	No	No	AAACD139F	Shares in the nature of encumbrance	0	0.00%	0.00%	238663700	20.00%	20.00%	0	0.00%	0.00%	238663700	20.00%	20.00%
2	DBX Advisors LLC	No	No	AAACD139F	Shares	0	0.00%	0.00%	45996	0.00%	0.00%	0	0.00%	0.00%	45996	0.00%	0.00%
Total						0	0.00%	0.00%	238709696	20.00%	20.00%	0	0.00%	0.00%	238709696	20.00%	20.00%

Place Hong Kong
Date 14-Nov-2022

Signature of the Authorised Signatory

A handwritten signature in black ink, appearing to be 'R. Murthy', written over a horizontal line.

Name: RAMANATHAPURA, Prasanna Venkatesha Murthy Manu
Designation: Vice President
Place: Deutsche Bank AG, Hong Kong Branch
Date: 14 November 2022